Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Boehringer Ingelheim GmbH : Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional’s FX125L and the somatotaxin portfolio to treat inflammation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/23/2012 | 11:04am CEST

Ingelheim, Germany and Cambridge, UK - 23 July 2012 Today, Boehringer Ingelheim, one of the world's leading pharmaceutical companies, and Funxional Therapeutics, a clinical-stage, asset-centric, private company, announced an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics' FX125L compound and somatotaxin programme. FX125L is a small molecule to treat a broad range of inflammatory diseases and was recently studied in a Phase 2 clinical trial in patients. Boehringer Ingelheim will be responsible for all further research, development and commercialisation of FX125L. Financial details of the transaction were not disclosed.

"Boehringer Ingelheim is delighted to add another promising compound to its development pipeline of drugs for the treatment of respiratory disease, one of its most important therapeutic areas", said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, "by acquiring the Funxional Therapeutics programme, we are looking forward to bringing a potential new therapy to patients, for instance those suffering from Asthma and COPD."

David Grainger, Founder and CSO of Funxional Therapeutics commented: "We are very pleased that the future development of FX125L and the somatotaxin programme will be now driven forward by Boehringer Ingelheim. They are a very impressive organisation and their people have the necessary knowledge, skills and experience to successfully develop FX125L."

Funxional Therapeutics was founded by David Grainger with initial investment from Index Ventures and Novo A/S in 2006. Ventech led the Series B financing. Index Ventures' partner and Chairman of the board, Michele Ollier said: "This acquisition is further validation of Index's business model and we congratulate the team who have delivered first class science and developed a very exciting molecule. They have done an extraordinary job of building this company."

Notes for Editors

About Somatotaxins
The somatotaxins are a new class of anti-inflammatory small molecules that exploit a new pathway discovered by FXT. This novel pathway is acting through the type-2 somatostatin receptor involved in the resolution of inflammation, and disrupted in chronic inflammatory diseases including asthma, COPD and rheumatoid arthritis. FXT's portfolio of somatotaxins exploit this pathway to deliver broad and potent anti-inflammatory activity, with different compounds optimised for topical, parenteral and oral delivery.

About Funxional Therapeutics
Funxional Therapeutics Ltd (FXT) is a privately held, clinical stage pharmaceutical company based in Cambridge, UK.

FXT's focus is on novel anti-inflammatory therapies that exploit a new pathway discovered by FXT. The lead product (FX125L, an orally available, once-daily small molecule which belongs to the new class of somatotaxins) has completed several Phase I studies in the USA. Attractive efficacy compared to existing therapeutic options, together with an adequate safety profile and dosing convenience, all position FX125L for clinical and commercial differentiation, with the potential eventually to become the first line therapy in major inflammatory diseases. Funxional Therapeutics was founded in 2005 based on intellectual property developed by Dr David Grainger and his colleagues at Cambridge University, in collaboration with Ipsen, a global specialty-driven pharmaceutical company targeting debilitating diseases in neurology, endocrinology, uro-oncology and hemophilia. Index Ventures and Novo A/S provided first round funding to initiate research and development activities. Further funding was led by Ventech.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news
Date Title
09:21p MACATAWA BANK CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
09:21p VCA INC. : to Present at Jefferies 2016 Healthcare Conference
09:21p Demand for Gluten-free and Healthy Products Will Significantly Propel the Global Fresh Baked Products Market Through 2020, Says Technavio
09:20p HUMANA : Change is in the works for Humana ACA exchange participation
09:20p GW PHARMACEUTICALS : The Cannabis Market Reaches New Heights
09:20pDJOil Upheaval Takes a Toll on Cutting Edge Projects
09:20p CANADIAN WORLD FUND : Investment Update-Unaudited
09:19p CALIAN : Declares Quarterly Dividend of $0.28 Per Share
09:19p NORDSON : MARCH's Compact ModVIA Plasma System is Easily Expandable from 4 to 8 Cells to Increase Machine Capacity for Production Demands
09:19p SINN FÉIN : Archibald condemns theft of election billboard and posters
Latest news
Advertisement
Hot News 
LSK : ‘Fiddler on the Roof' coming to CHT on June 10
AVOLON : delivers its first Airbus A320neo aircraft
MARECHALE CAPITAL : Unaware Of Any Reason For Share Price Jump
DEUTSCHE POSTBANK : Glory, Deutsche Postbank implement closed-loop cash-handling system
Purcell Julie & Lefkowitz LLP Is Investigating Histogenics Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Most Read News
05/03 Lateral Gold Announces Proposed RTO Transaction with CANHaul International
01:57p Global stocks retreat for second day on growth worries
05/03 Cascade Financial Services to be Acquired by an Affiliate of Centerbridge Partners, L.P.
05/03 CREDIT CHINA : Announces Investment in BitFury, Joint venture to jointly promote Blockchain technology in China, Strengthen information security and Group's capability in Internet finance
05/03 CRAMER : Federal Regulators Have No Answer for Need for Devastating Mining Rule
Most recommended articles
05/03DJUBS Shares Drop As Profit Slumps
03:20pDJOil Upheaval Takes a Toll on Cutting Edge Projects
03:16p U.S., Takata confirm recall of 35 million-40 million Takata air bag inflators
03:12p Merkel says working for U.S.-EU trade deal this year
03:01p Amazon, Hyatt named top picks at hedge-fund event